Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Paclitaxel (PTX) is a primary treatment for esophageal squamous cell cancer (ESCC).
• Drug resistance, particularly to PTX, frequently leads to treatment failure in ESCC.
• Stathmin overexpression is linked to chemoresistance in various cancers.

Purpose of the Study:

• To investigate the impact of stathmin gene silencing on the efficacy of PTX in ESCC.
• To evaluate the potential of combining PTX with stathmin siRNA for improved ESCC treatment.

Main Methods:

• Utilized small interfering RNA (siRNA) to silence the stathmin gene in ESCC cell lines (EC9706 and Eca-109).
• Assessed the effects of stathmin gene silencing alone and in combination with PTX on cell proliferation, cell cycle progression, and apoptosis.
• Measured stathmin mRNA and protein levels following siRNA transfection.

Main Results:

• Stathmin siRNA effectively reduced stathmin mRNA and protein expression in ESCC cell lines.
• Combined treatment with PTX and stathmin siRNA significantly inhibited ESCC cell proliferation.
• The combination therapy led to a higher proportion of cells in the G2/M phase, increased apoptosis, and observable morphological changes.

Conclusions:

• Stathmin gene silencing can overcome PTX resistance in ESCC.
• Combining PTX with stathmin siRNA demonstrates potential as an enhanced therapeutic strategy for ESCC.
• Targeting stathmin offers a promising approach to improve the clinical outcomes of PTX chemotherapy in ESCC.